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Abstract
A multicompartment mathematical model is presented with the goal of studying the
role of dose-dense protocols in the context of combination cancer chemotherapy.
Dose-dense protocols aim at reducing the period between courses of chemotherapy
from three to two weeks or less, in order to avoid the regrowth of the tumor during the
meantime and achieve maximum cell kill at the end of the treatment. Inspired by
clinical trials, we carry out a randomized computational study to systematically
compare a variety of protocols using two drugs of different specificity. Our results
suggest that cycle specific drugs can be administered at low doses between courses of
treatment to arrest the relapse of the tumor. This might be a better strategy than
reducing the period between cycles.
Author summary
Chemotherapeutic drugs for the treatment of cancer are currently delivered in periodic
cycles to allow healthy tissues to recover from their cytotoxic effects. Unfortunately,
this recovery window allows the tumor to regrow between cycles as well. It has been
observed that a reduction of the periodicity from three to two weeks can be beneficial
without introducing higher toxicities. These new chemotherapeutic protocols are
known under the term dose-dense chemotherapy. We perform a computational study
to assess the limitations of the dose-dense approach and suggest possible alternatives.
Introduction
Overcoming the toxic side-effects of chemotherapeutic drugs on healthy tissues in the
short term, as well as the development of drug resistance of cancer cells to such
medications in the long run, are the two key cornerstones in the improvement of
cytotoxic drug therapy [1–3]. These two limiting factors put before, the rest of our
research efforts must concentrate on the particular arrangement of protocols.
Randomized trials carried out along the last forty years have demonstrated that the
way in which protocols are organized is of great relevance as well [4–7]. For instance,
breast cancer trialists have revealed that, in addition to the drug dose-intensity, the
periodicity of the cycles of chemotherapy affects the patients’ outcome as well [8].
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Accordingly, a sequential administration of two drugs can be more beneficial than the
same drugs given alternately [4]. In particular, a reduction of the period between
cycles of chemotherapy from three to two weeks has introduced moderate but
statistically significant benefits in disease free survival at five years and overall
survival [8]. Fortunately, this can be achieved without entailing higher toxicities with
the assistance of granulocyte colony-stimulating factor.
The increase in the frequency of drug administration has been termed dose-dense
chemotherapy, because when the dose is graphically represented against time, these
protocols look more tight [9]. Of course, from a physical point of view, the temporal
density of a certain magnitude can also be raised by increasing the amount of such
physical magnitude while keeping the same distribution over time. On the other hand,
dose-intensity is commonly defined in the field of oncology as an average by dividing
the total dose of a drug administrated during a treatment by the duration of such
treatment [8]. Thus, as currently defined and utilized, dose-density and dose-intensity
are two mudding and redundantly interrelated concepts. To avoid any sort of
confusion we unwind these two ideas by adopting the following criteria [10]. The term
dose-density is here reserved to denote a variation in the periodicity of the cycles of
chemotherapy when the dose per cycle is kept constant, while the term dose-intensity
of a drug is hereinafter referred to an increase in the amount of dose administered per
cycle.
From a theoretical point of view, the ground on which dose-dense chemotherapy
settles is known as the Norton-Simon hypothesis. This hypothesis states that the rate
of destruction by chemotherapeutic drugs is proportional to the rate of growth of an
identical unperturbed tumor [11]. This statement is founded on the notion of
mitotoxicity, which proclaims that chemotherapy acts more efficiently on the cells that
are rapidly proliferating within a tissue [1]. Consequently, since only a fraction of the
cells that shape a solid tumor are actively dividing [12, 13], and bearing in mind that
more cells in proportion turn into the quiescent state so as to render the growth of the
tumor sigmoid [14], the impact of chemotherapy should be stronger for smaller tumors.
This effect would hinder the efficiency of chemotherapy because, at some point of the
growth curve, the regrowth between cycles would prevail over the destruction caused
by the drugs during that same cycle. Note that tumors tend to regrow more rapidly
after a cycle of chemotherapy, becoming less sensitive at the end of such period of
time, when the subsequent cycle arrives.
In summary, the progressive doubling time dilation of a growing solid tumor defies
the log-kill paradigm that has dominated traditional chemotherapy over decades [15],
which is being curtailed to non-solid malignancies nowadays. These supporting
arguments notwithstanding, it has been recently demonstrated that dose-density
might be pertinent even in the absence of any hypothesis affecting the particular
nature of the tumor’s growth [10]. However, enthusiasm must be prevented at the
same time, since the benefits of dose-dense chemotherapy are still being the subject of
intense experimental research and scientific debate [16]. We recall that the biological
mechanism by which a certain drug inflicts its damage in practice might not
correspond exactly to the one for which it was originally conceived [17].
Bearing all these facts in mind, the appearance of dose-dense protocols for the
treatment of solid tumors has been at all events an important breakthrough in breast
and ovarian cancer. Furthermore, it is also posing crucial questions concerning the
nature of solid tumor growth and its dynamical response driven by complex
combination therapies [9]. Always bounded to experimental verification, needless to
say, many of these questions can be better addressed within the framework of
mathematical and in silico modeling [18]. In the present work we propose a
multidimensional ordinary differential equation (ODE) model for cancer chemotherapy
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Fig 1. Schematic representation of the cell cycle. (a) In the life of an
eukaryotic cell, a new individual is born by mitotis (M) and starts its journey at Gap
1 (G1). If the conditions are adequate, it proceeds to replicate its DNA during the
phase of synthesis (S). If they are not, the cell exists the cycle and becomes quiescent
(G0). After DNA synthesis the cell resumes its growth through the Gap 2 phase (G2)
and, if there is no DNA damage, a new mitosis begins. The whole cycle lasts around
twenty four hours for a typical proliferating human cell [31]. (b) Three phases of the
cell cycle are joined into a single compartment, yielding a new model where the arrows
represent the flow direction and constant rates between compartments.
to investigate under which conditions dose-dense protocols are more or less
advantageous. As far as we are concerned, the present work represents the first
mathematical and computational approach to the study of the dose-dense principle in
a cytotoxic combination therapy [19–23]. We disregard toxicity models in this study,
since it is not our purpose to develop specific protocols for a certain class of tumors,
which could sometimes be regarded with skepticism [24]. We would rather find general
guiding principles that may aid clinicians to bias their decisions in their proposal of
better forthcoming chemotherapeutic protocols.
1 Methods
1.1 Model description
A general multicompartment model for cancer chemotherapy can be built from
preceding modeling attempts [25–30]. Since the cell cycle comprises four phases
(mitosis, Gap 1, synthesis and Gap 2) and cells can also be quiescent (Gap 0), we
consider a model with five different compartments representing the cell populations in
each of them (see Fig. 1(a)).
The use of different compartments is relevant since some drugs destroy only cells in
a specific phase of the cell cycle. We assign to each of these compartments a number j
between one and five, respectively. Therefore, the five cell populations can be
represented by a vector ~P (t), whose components can be written in tensor form as
Pj(t). We allocate the first compartment (j = 1) to mitotic cells, while quiescent cells
are inserted in the last compartment (j = 5). Following previous works [28], we
assume that only quiescent cells die from necrosis. On the contrary, the apoptotic
pathway might be activated in any compartment [32]. However, tumors frequently
evolve towards states of low apoptotic index quickly [28]. Consequently, and for
computational simplicity, we sweep apoptosis under the rug of the proliferation term,
by considering that this pathway simply reduces the net growth rate of tumor cells.
Finally, every equation is equipped with two more terms. The first of them represents
the rate of flow between adjacent compartments, while the second one models the
action of cytotoxic drugs on each compartment. Broadly speaking, cytotoxic drugs can
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Fig 2. A tumor spheroid. A spherical tumor showing several layers with cell
populations displaying different kinetic status. The various gradients of chemicals
from the interior to the outermost layer are schematically represented. As can be seen,
only a fraction of cells, placed at the most exterior region, are actively proliferating.
The different layers correspond to different compartments of the model (from Ref. [12]
under license CC BY-SA 4.0).
be classified as cycle specific (CS) or cycle non-specific (CNS). The former inflict their
damage at a specific point of the cycle of the cell, while the second can destroy cells
independently of their kinetic status. Therefore, the two vector variables ~Cs(t) and
~Cn(t) symbolize the different types of drugs that have to be delivered to the patient,
respectively. The dimension of each vector is given by the number of drugs scheduled
in the treatment. In summary, the differential equation governing the dynamics of
each population Pj(t) in the system can be written as
dPj
dt
= δ1jg(~P )Pj − δ5jn(~P )Pj +
5∑
i=1
wji(~P )Pi − kj(~P , ~Cs, ~Cn)Pj , (1)
where δij is the Kronecker delta and j = 1, ..., 5. As thoroughly described ahead, the
functions g(~P ) and n(~P ) are nonlinear functions representing the fractional cell
growth of the tumor cells in the mitotic compartment and the fractional cell death due
to necrosis in the quiescent compartment. The functions wji(~P ) and kj(~P , ~Cs, ~Cn) are
nonlinear functions representing the fractional cell flow between compartments and
the fractional cell kill of chemotherapeutic drugs on each compartment, respectively. If
the cell cycle is regarded as a Markov chain, the terms wji(~P ) are related to the
transition matrix. On the other hand, the detailed functions ~Cs and ~Cn depend on the
pharmacokinetical model used and the way in which drugs are administered. Note
that this inhomogeneous five-dimensional model is constituted by two well
differentiated parts. The three first terms on the right hand side of equation (1) define
the cell kinetics and include the turnover of cells from one stage of the cell cycle to
another, as well as the birth of tumor cells and their death from other causes different
from cytotoxic treatment. The remaining fourth term on the right hand side of the
same equation represents precisely the destruction of tumor cells by the cytotoxic
agents. In the next lines we particularize the present model to meet the needs of the
present work.
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1.2 Kinetic model
In practice, one or more compartments of the previous general model can be merged
into a single compartment, reducing the dimensionality of the problem (see Fig. 1(b)).
For example, in the present work, there is only one CS drug and another CNS drug.
Therefore, only three kinetic compartments are needed. If we assume that the cycle
specific drug only targets cells in the phase of synthesis, as it frequently occurs, two
compartments are required to represent cells that are actively dividing. One of these
compartments contains cells that are in the synthesis phase at a particular instant of
time t. This cell population is represented henceforth by the variable S(t), while the
remaining cells comprise all those cells that are in the complementary part of the cell
cycle (mitosis, Gap 1 and Gap 2). We just gather these three compartments into a
single one and refer to the cell population contained in it as mitotic, representing it
mathematically by the letter M(t). To conclude, one more cell population Q(t) is
included to model those resting cells that make up the quiescent compartment (see
Fig. 2). Therefore, in this first study we shall utilize the three-dimensional model
given by the following system of differential equations
dM
dt
= (r − v)M + uS − w(P )M + pQ
dS
dt
= −uS + vM
dQ
dt
= w(P )M − (p+ n)Q,
(2)
where r stands for the net growth constant rate resulting from proliferation and
apoptosis of the cells in the mitotic pocket and n describes the rate at which quiescent
cells die from necrosis. These terms correspond to the functions g(~P ) and n(~P ) in
equation (1), which are chosen to be constants. The parameters u, v are the flow
constant rates of cells from the s-phase to the mitotic population and vice versa. The
term w(P ) and p are the rates describing the speed at which cells flow from the
mitotic compartment to the G0 phase and vice versa. Now, these functions correspond
to the functions wji(~P ) in the original model. The variable P (t) represents the whole
tumor cell population resulting from adding the cells in all the compartments, i. e.,
the relation P (t) = M(t) + S(t) +Q(t) holds. Note that the total tumor cell
population is governed by the net growth rate balanced by the rate of necrosis
dP
dt
= rM − nQ. (3)
Most of the fractional cell functions are considered constant for simplicity,
following previous works [28] and traditional quasispecies models [34]. However, the
flow rate between mitotic cells and quiescent cells is more generally assumed to be
governed by the linear term w(P )M . The reason why this is so is that we want the
model to represent limited growth following a sigmoid function up to a certain
maximum number of tumor cells P ∗ = K. This stable fixed value is frequently known
as the carrying capacity of the tumor and we shall follow this terminology here. More
specifically, we assume logistic growth [35–37] for mathematical simplicity.
Nevertheless, other types of sigmoid functions, such as Gompertzian growth or a
Richards’ type of growth can be used instead, since they are all generated by diffusive
long range cell interactions [38]. In short, we consider that the flow rate of mitotic
cells to the resting pocket obeys a linear function w(P ) = qP , which gives rise to a
logistic type of growth.
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We now describe how to compute the model parameters describing the rates of flow
u, v, q between compartments in terms of the other parameters, which are more
amenable to the experimental practice and for which we have several values in the
literature [28]. These better known parameters are the constant rate of mitosis r, the
turnover of mitotic to quiescent cells p, the proliferative index, here denoted as ℘ and
defined as
℘(t) =
M(t) + S(t)
P (t)
, (4)
and the fraction of time f that cells spend in the phase of synthesis.
The parameters u and v can be expressed in terms of r by considering the time
spent in each phase of the cycle by a human cell. These constant rates can be
estimated by means of the following argument. If we name the total cell cycle time by
τ and the cell cycle of the synthesis phase is denoted as τS , while the remaining time
of the cycle is written as τM , we have τ = τS + τM . In particular τS = fτ and
τM = (1− f)τ are fulfilled. Now, for a geometric growth, the doubling time is
inversely proportional to r, which allows us to write u = r/f and v = r/(1 − f). On
the side of the variables we have that at equilibrium the rates are zero
dM/dt = dS/dt = dQ/dt = 0 and, consequently, also the relation dP/dt = 0 holds.
Now, we name the values of the cell populations at equilibrium as M∗, S∗ and Q∗ and
assume that they are different from zero. Then, bearing in mind that
P ∗ = M∗ + S∗ +Q∗ = K, it is straightforward to obtain from the second identity
appearing in equation (2) that S∗ =M∗v/u, and from equation (3) that Q∗ = M∗r/n.
Using these two results and the equations obtained from the conditions
dM/dt = dS/dt = 0, the constraint
q =
r
K
(
1 +
p
n
)
(5)
is implied. Furthermore, making use of equation (2) we can also derive the size of each
cell population at equilibrium, which reads
M∗ =
K
1 + v/u+ r/n
, S∗ =
Kv/u
1 + v/u+ r/n
and Q∗ =
Kr/n
1 + v/u+ r/n
. (6)
From these three values it is easy to check that the proliferative index at equilibrium is
written as
℘∗ =
1 + v/u
1 + v/u+ r/n
, (7)
from which we can derive the following parameter relation for the constant rate of
necrosis n as
n = r (1− f)
(
℘∗
1− ℘∗
)
. (8)
In the numerical study conducted in the section containing our results we present all
the parameter values of the model, which are derived from the elementary parameters
r, f, ℘∗, p by means of the preceding equations.
1.3 The fractional cell kill of cytotoxic drugs
Once the kinetic model and its parameters have been established, we proceed to
introduce the fractional cell kill of cytotoxic drugs. Just as a reminder, and because
sometimes the term rate is loosely used to refer a constant rate [39, 40] or the
fractional cell kill itself [40], we clarify this concept. It describes the rate at which a
cell population is reduced to a fraction of itself after a fixed period of time. If the cell
population presents a constant fractional killing, it means that it decays exponentially
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Fig 3. Chemotherapy protocol. A protocol is represented schematically, showing
the function I(t) for each drug. In particular, the size of each bar represents the value
of this function. In this figure we showed the CS and CNS drugs delivered
concurrently with a period T of three weeks using different doses D for each of them.
The time duration of each infusion τa, however, is the same for the two drugs.
in time. The fractional cell kill should be then identified with the constant rate of the
decay, being both in direct relation. Therefore, the fractional cell kill must be
rigorously defined from a mathematical point of view as the rate at which the
logarithm of a cell population P decreases as a consequence of some biological process
(d lnP/dt), as it is done in previous works [40].
In the present case, such attrition is caused by cytotoxic agents. To work out the
mathematical nature of the function k(P,C) that describes the cell kill by a
chemotherapeutic drug we appeal to past works on this subject [41]. There, the
following function is proposed
k(P,C) =
µ
1 + σP/K
(
1− e−ρC
)
, (9)
where C(t) is the concentration of the drug at the tumor site and µ is the maximum
fractional cell kill achievable by the drug, when it is ideally given at an infinite dose to
sufficiently small (exponentially growing) tumors. The term 1− e−ρC is based on the
Exponential Kill Model [33]. This mechanistic model was developed in conformity
with in vitro data and has also been tested against in vivo experiments with
mice [33, 36]. Contrary to traditional log-kill models, it exhibits saturation of the cell
kill as the drug concentration is raised. The steepness of the dose-response curve is
related to the sensitivity ρ of a tumor cell line to a particular drug. Simply put, for a
nascent tumor the parameter µ would be the maximum constant rate of destruction
achievable at high doses. On the other hand, the parameter ρ tells us how the
response to the drug is modified as the cells become increasingly resistant. This
reduction in sensitivity to the drugs is reflected by a smaller value of the parameter ρ.
Finally, in another investigation [41] we derive and explain in great detail the
Michaelis-Menten dependence of the cell kill rate on the total tumor size population
P (t). It has been introduced in the model in order to account for the Norton-Simon
hypothesis, whose intensity is condensed in the parameter σ. As the tumor gets bigger
and approaches its carrying capacity, the maximum fractional cell kill reduces from µ
to the value µ/(1 + σ), with σ > 0.
Since we only deliver one cycle specific drug Cs and another cycle non-specific drug
Cn in the foregoing investigation, the whole set of differential equations together with
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chemotherapy can be written as
dM
dt
= FM (M,S,Q)−
µn
1 + σnP/K
(
1− e−ρnCn
)
M
dS
dt
= FS(M,S,Q)−
µn
1 + σnP/K
(
1− e−ρnCn
)
S −
µs
1 + σsP/K
(
1− e−ρsCs
)
S
dQ
dt
= FQ(M,S,Q)− ǫ
µn
1 + σnP/K
(
1− e−ρnCn
)
Q,
(10)
where the functions FJ (M,S,Q) represent the kinetic equations for each compartment
respectively, with J = {M,S,Q}. Note that a new parameter ǫ has been introduced in
the third equation. It is linked to the extent to which non-specific drugs destroy cells
in the quiescent phase. It is frequently assumed that, because of their mechanism of
action, CNS drugs destroy quiescent cells to the same extent as they damage cycling
cells [28]. From a logical point of view, this would be certainly so, even only by
definition. However, although the mechanism of action can be clearly identified
sometimes for a drug, on many occasions the death of the cell is only made effective
once it reenters the cell cycle [17]. The notion of a cell kill that is totally independent
of the kinetic status of the cell clearly challenges the paradigm of mitotoxicity. Even
so, the fact that the proliferation rates in many chemosensitive human cancers are low
clash with such paradigm, suggesting to some extent that the mechanisms of
destruction might be different as those conventionally claimed [1, 17, 24]. Therefore, a
value ǫ in the interval [0, 1] is deserved to modulate the effect of CNS drugs on resting
cells.
1.4 Pharmacokinetics and protocols of chemotherapy
It remains to be introduced the pharmacokinetics of the present model, which
determines the dynamics of the concentration of each drug C(t) at the tumor site. As
in previous works on chemotherapy [27, 36, 37], we assume a one-compartment model
and first order pharmacokinetics, which in some situations can be considered as a
good approximation to the clinical practice [42]. Hence, the differential equation
governing the concentration of the drug simply reads
dC
dt
= I(t)− keC, (11)
where I(t) is the function representing the rate of drug flow into the body (i. e. the
instantaneous dose-intensity) while ke is the rate of elimination of the drug from the
bloodstream. The half-life can be computed from this constant rate by taking ln 2/ke.
Concerning the drug delivery, we assume that every drug is administered
intravenously at constant speed during a time τa in cycles of period T . Therefore, a
typical protocol of chemotherapy can be schematically represented as in Fig. 3. If the
total drug dose given in a course of chemotherapy is D, then the instantaneous
dose-intensity I(t) is mathematically expressed as the square function
I(t) =


D
τa
for t(mod T ) ∈ [0, τa)
0 for t(mod T ) ∈ [τa, T )
. (12)
The solution to equation (11) with a drug input given by equation (12), when a
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Fig 4. The drug concentration. The time series of the drug concentration for six
cycles of chemotherapy administered every T weeks. Each course of chemotherapy
consists of a continuous infusion of drug that lasts a time τa. Hence the rate of
infusion is mathematically represented by a square function of height D/τa. The
constant rate of elimination of the drug from the bloodstream is ke. Asymptotically, a
steady oscillation between two values of the concentration C∗min and C
∗
max is attained.
number of N + 1 chemotherapeutic cycles have been delivered, yields
C(t) =


D
keτa
(1− e−ket) + aN (t) for t(mod T ) ∈ [0, τa)
D
keτa
(ekeτa − 1)e−ket + aN(t) for t(mod T ) ∈ [τa, T )
, (13)
where aN (t) represents the decaying accumulated drug concentration at the N + 1-th
cycle of chemotherapy, which equals zero for the first cycle (a0(t) = 0) and it is equal
to
aN (t) =
D
keτa
(ekeτa − 1)e−ket
N∑
n=1
e−nkeT (14)
for the subsequent cycles. As shown in Fig. 4, when the number of cycles tends to
infinity (N →∞), the concentration reaches a steady state periodic oscillation C∗(t)
between a minimum value
C∗min =
D
keτa
ekeτa − 1
ekeT − 1
(15)
and a maximum value C∗max = C
∗
mine
ke(T−τa). Since the period between cycles of
chemotherapy commonly spans a few weeks, whereas the drug is eliminated rather
quickly in comparison (around a day), the accumulation of drug is not usually very
important, unless τa is comparable to T .
2 Results
The most important part of the results presented here concerns the randomized
computational study along which we compare several types of protocols in the
six-dimensional parameter space spanned by the parameters µs, µn, ρs, ρn, σs and σn.
However, to acquire some intuition on the differences between cycle specific and cycle
non-specific drugs, we thoroughly investigate the role of these drugs separately in the
first place. These prior computations will enable a discussion on the role of the
parameter ǫ, which describes the relative effect of CNS drugs on resting cells,
compared to their cycling counterparts. Moreover, they will permit us to uncover the
evolution of the proliferative index along the treatment. As shown promptly, the
proliferative fraction acts as a limiting factor to dose-densification when the quiescent
compartment is barely chemosensitive.
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Fig 5. Administration of a single CS drug. The evolution of the three cell
populations when four cycles of Ds = 90 mg of a s-specific drug are delivered every
two weeks intravenously (τ = 1 min). The drug dose is plotted in the background for
clarity, disregarding its specific values. (a) The evolution of dividing cells in the
mitotic (red) and the synthetic (green) compartments. (b) The quiescent population
(blue) reduces continuously since these cells enter the cell cycle as the replicating
population is reduced. The evolution of the whole tumor (magenta) is also shown for
completeness. (c) The proliferative fraction increases modestly in average, because the
quiescent compartment is continuously feeding the dividing one.
As far as the kinetic parameters of the model are concerned, we give their values in
this preamble. Such values shall be used for all the simulations, unless otherwise
specified. We consider a tumor whose maximum rate of growth is r = 0.9 weeks−1 and
with a value of the carrying capacity of K = 109 cells, which are derived from
experimental values in references [36, 39]. An extremely fast growing tumor would be
one in which all cells were ceaselessly dividing through mitosis in the absence of
apoptosis. Since the cell cycle of a human cell lasts approximately one day, this
corresponds to an exponentially growing tumor with a constant rate value of
r = 4.85 weeks−1. Therefore, we are considering a quite aggressive tumor for which
the rate of apoptosis is rather low. The carrying capacity corresponds to a detectable
premetastatic tumor mass of approximately one gram. We recall that limiting values
of deadly tumor masses round numbers of K = 1012 cells [1]. The original size of the
tumor is considered to be P0 = 9× 10
8 cells, divided among the three compartments
as given by their equilibrium distribution, represented by equation (6). We take a
typical value of ke = 4.85 weeks
−1 for the CNS drug and ke = 9.55 weeks
−1 for the CS
one. These two values correspond to a half-life of approximately one day and less than
a half a day, respectively [41]. The proliferative index is considered to be ℘∗ = 0.35,
which is a reasonable intermediate value within the range appearing in previous works
based on empirical data [28]. The value of p is chosen to be 0.35 weeks−1, which is
exactly the same value assumed in the last cited work, and which is also based on
experimental evidence [43–45]. This value settles the constant rate of necrosis to
approximately n = 0.3 weeks−1 by means of equation (8). Again, this amount is also
of the order of other values appearing in the literature [28], which results in a necrotic
fraction compatible with the experimental data gathered from in vivo experiments [46].
The value of q is derived from equation (5) after an elementary computation, and
results to be q = 1.95× 10−9 weeks−1cell−1. To conclude, since the time spent in the
s-phase of the cycle of a typical human cell is two fifths of the whole cycle, we have
f = 0.4. As we argued before u = r/f and v = r/(1 − f), thus we obtain that
u = 2.25 weeks−1 and v = 1.5 weeks−1.
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Fig 6. Administration of a single CNS drug. The evolution of the three cell
populations when four cycles of Dn = 60 mg of a non-specific drug are delivered every
three weeks intravenously (τn = 1 min) assuming that ǫ = 0 in the first case, which
means that quiescent cells are not affected by CNS drugs. Then a moderate
destruction with ǫ = 0.2 is considered. (a) The evolution of cells in the mitotic (red)
and the synthetic (green) compartments. (b) The quiescent population (blue) reduces
continuously again. The evolution of the whole tumor (magenta) is plotted as well. (c)
The proliferative fraction increases now very steeply, since the number of dividing cells
increases as the quiescent cells flow from the proliferating compartment. (d-f) The
same corresponding figures for the case ǫ = 0.2, where quiescent cells are being
destroyed by the drug as well. As expected, the proliferative index reaches even higher
values than for the previous case.
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Fig 7. A limitation to dose-density. The evolution of the three cell populations
when four cycles of a non-specific drug at a dose Dn = 60 mg are delivered every week
intravenously (τn = 1 min), assuming that ǫ = 0. (a) The evolution of cells in the
mitotic (red) and the (green) compartments. (b) The quiescent population (blue)
reduces continuously, but now the replicating cells are not allowed to regrow between
cycles, leading to a very small proliferating fraction. The evolution of the whole tumor
(magenta) is plotted as well. (c) The time series of the proliferative fraction ℘, which
is kept at a very small value close to 0.2 due to the higher density of the protocol.
2.1 Cycle specific and cycle non-specific drugs separately
We begin by studying the role of the administration of a CS drug alone. If desired, we
consider µn = 0.0 weeks
−1 in the model equations (10). The value of the sensitivity is
set to ρs = 1.0 mg
−1, which is within values appearing in previous works for cells
sensitive to methotrexate [33], an antifolate drug that acts during the s-phase of the
cycle. For reasons explained somewhere else [10, 41], the maximum fractional cell kill
is set to µs = 4.0 weeks
−1. As shown in previous works [41], this value corresponds to
a moderate value of a drug that is capable of tumor shrinking. Finally, the parameter
σs = 1.0 is set, corresponding to a value for which the Norton-Simon hypothesis
applies rather weakly [41]. It means that the rate of kill is reduced to half of its
maximum value as the tumor gets close enough to the carrying capacity. A dose of a
CS drug Ds = 90 mg is administered intravenously (τs = 1 min) every two weeks
(Ts = 2 weeks). The values of the dose and the drug periodicity are within values
frequently appearing in standard protocols of chemotherapy1. For example, the CS
drug methotrexate can be administered at high doses of D = 50 mg m−2 for an adult
male [47]. Since the average surface body area of an adult male is around 1.8 m2, a
value of Ds = 90 mg can be estimated. Nevertheless, we recall that a great variability
in the parameters µ, ρ and σ is expected in practice [33]. For this reason, we design
the randomized numerical trial presented in the next section.
As shown in Figs. 5(a) and (b), when a CS drug destroys tumor cells in its specific
compartment, this cell population is naturally reduced. As cells in the s-phase are
destroyed, less cells flow from the synthesis phase to the mitotic one, so that M(t)
mimics S(t), although the variations are less pronounced, more smooth and present a
delay of a couple of days. Once the drug is eliminated from the organism, the tumor
cells in the mitotic pocket regrow during the remaining part of the cycle. As the
dividing tumor cells are wiped out, the resting cells abandon their state of quiescence
and reenter the cell cycle. This effect produces a continuous reduction of the quiescent
compartment. As can be seen in Fig. 5(c), the regrowth of tumor cells between cycles
of chemotherapy and the draining of resting cells reinforce each other contributing to
1Information about standard protocols of chemotherapy has been drawn from < http :
//www.bccancer.bc.ca/health− professionals/clinical− resources/chemotherapy− protocols >
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Fig 8. Parameter space. The survival fraction at the nadir of the treatment
sf = P (tnad)/P (0) is computed for a square grid of values in the parameter space
(σn, µn) of the CNS drug. The values of the parameter µn are given relative to r. A
periodic protocol of Dn = 60 mg administered intravenously with Tn = 3 weeks is
computed. Then the same values are computed for a denser protocol with
Tn = 1 week, and the ln(sf/s˜f ) is shown, where the tilde stands for the denser
protocol. The log-ratio corresponds to the colorbar, where the black color has been
assigned to values smaller or equal to zero. We see that for high values of µn and
small values of σn dose-density fails to reduce the survival fraction at the nadir and
might be even counterproductive.
an average increase of the proliferative index. However, this increase and the periodic
oscillations around it are very modest for CS drugs.
Now we examine the effect of administering CNS drugs on the model. For this
purpose, we consider a dose of drug Dn = 60 mg administered intravenously
(τs = 1 min) every three weeks (Tn = 3 weeks), which are typical for the drug
doxorubicine, used in chemotherapy for locally advanced breast cancer. The parameter
values used in these simulations are µn = 4.0 weeks
−1 for the maximum fractional cell
kill, ρ = 1.0 mg−1 for the sensitivity and σ = 1.0 for the parameter simulating the
Norton-Simon effect. In these simulations we assume that CNS drugs do not affect the
quiescent compartment, thus ǫ = 0. As shown in Fig. 6(a) and (b), CNS drugs destroy
tumor cells in the whole dividing compartment, producing a greater tumor cell decay.
However, the regrowth between cycles is also higher now, and since the quiescent cells
are resuming their cell cycle, these effects synergize to produce oscillations that grow
in amplitude shooting up the proliferative index. In Figs. 6(d) and (e) the same results
are investigated, by considering a certain destruction of quiescent cells by the CNS
drug, as is commonly accepted [17, 28]. However, following a principle of prudence, we
consider a small value ǫ = 0.2, which is respectful with the paradigm of mitotoxicity as
well [1]. This phenomenon produces an even stronger boost of the proliferative index.
Now its oscillations are smaller, because the transfer of cells from the quiescent
compartment reduces slightly. We note that a possible and simplified way of modeling
the most strict version of the Norton-Simon hypothesis, would be to consider the
parameters ǫ and σ both equal to zero.
These results clearly suggest that, contrary to the philosophy of dose-density,
allowing some time between cycles has the benefit of maintaining a high proliferative
fraction. In turn, it is then expected that if we push the dose-density too much,
protocols might become less effective, unless quiescent cells are as chemosensitive as
cancer cells are. This idea is corroborated when we compute the same protocol in
Figs. 7(a) and (b) with the same drug but at an increased frequency of one week. The
April 9, 2019 13/22
Fig 9. Randomized numerical trial. A total number of seven chemotherapeutic
protocols are compared among them. Unless otherwise specified, all the drugs are
administered intravenously (τ = 1 min). (a) The reference protocol, for which a CS
and a CNS drug are given concurrently every three weeks at doses Ds = 90 mg and
Dn = 60 mg, respectively. (b) A protocol that is twice denser than the reference in the
CS drug. (c) A protocol that is twice denser than the reference in the CNS drug. (d)
A protocol with a higher frequency but Ds = 45 mg, which equals to the same total
dose. (e) A protocol with the same total dose for the CS drug as the reference
(360 mg), but administered continuously. (f) A protocol for which the two drugs are
given alternately every one and a half weeks. (g) A sequential protocol, where one of
the drugs (CNS) is given in the first place every one and a half weeks, while the
second is given right after (CS), with identical frequency.
resulting plot for the proliferative fraction (see Fig. 7(c)) indicates that some time is
required for the quiescent cells to reenter the cell cycle and regrow, posing a limit on
the frequency reduction craved by dose-dense protocols. Furthermore, and as a
completely novel result, we show in Fig. 8 that when comparing the survival fraction
at the nadir sf = P (tnad)/P (0) of two treatments for ǫ = 0, one being three times
more dense that the other, there exist parameter values for which dose-density is not
recommendable. We consider this statement an important revelation of the present
model compared to previous investigations on this topic, where the dose-dense
principle was unequivocally advocated [10, 41].
2.2 Randomized computational trial
Now we accomplish a randomized comparative study between several types of
chemotherapeutic protocols. Inspired by clinical trials, we represent a vast number of
different virtual patients (so to speak) by letting the parameters µs, µn fluctuate in
the range, [0.1, 4.5] with a uniform distribution. The parameters σs and σn are
selected from the interval [0.1, 5.0] following the same recipe. Finally, the values of ρs,
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Fig 10. Sequential or alternating? A numerical trial comprising 400.000 random
and uniformly chosen events in the six-dimensional parameter space
(µs, σs, ρs, µn, σn, ρn) is carried out. The parameters µ and σ take values in the
intervals [0.1, 4.5] and [0.1, 5.0] respectively, while the parameters ρ are selected in the
range [0.1, 1.0]. The number of events with a particular survival fraction at the nadir
of the treatment are shown for the sequential (green) and the alternating (magenta)
regimes, showing the greater benefits of the former.
ρn are picked at random in the range [0.1, 1.0] and ǫ is considered to be equal to 0.2.
This set of values is enough to model both chemosensitive and resistant cell clones [41],
a considerable heterogeneity of drug responses to the drugs and a considerable degree
of mitotoxicity. As far as we have investigated, doubling the size of the parameter
intervals does not produce a substantial variation of our results. We use a total count
of 400.000 parameter values for each protocol, which has proven to be sufficient to give
a convergent probability distribution at different scales and allow fast computations at
the same time. Finally, for each point in the six-dimensional parameter space and
every protocol, we compute the survival fraction at the nadir sf = P (tnad)/P (0), using
the same initial conditions as in the simulations of the previous section. This
effectiveness criterion has been adopted in previous works [28, 41]. Consequently, we
recall that, since in the present study we are not explicitly modeling toxicity, the
benefits or the effectiveness of a protocol should not be read from a clinical point of
view, but from a theoretical one instead.
We now briefly discuss the design of the protocols. As seen in Fig. 9 seven different
protocols are computed. A first reference protocol for which the two drugs (CS and
CNS) are delivered concurrently every three weeks at doses appearing in the previous
sections. The duration of the infusions also remains unchanged (τ = 1 min) with
respect to the previous simulations. Then, two more protocols are computed to test
the benefits of dose-densification in relation to the specificity of the drug. The former
protocol is twice denser in the CS drug, while the latter is more tight for the CNS
drug. The frequency is doubled in order to test protocols that are limiting in the time
scale frequently used in the clinical practice (order of weeks). Now, the two next
protocols are conceived to test an alternative way of avoiding tumor growth between
cycles, compared to dose-densification. For this purpose, we use the CS-drug
administered at constant total doses, and increase progressively the frequency of drug
administration. Therefore, the fourth protocol for which the CS drugs is given at half
the original dose (Ds = 45 mg), but delivered every one and a half weeks. Then, the
same total dose of Ds = 360 mg is delivered continuously. In this last case the drug
concentration is very small to destroy the tumor, but enough to halt its regrowth
between cycles of the CNS drug. Finally we introduce two additional protocols to
compare the relative benefits of sequential against alternating protocols. To some
extent, this evaluation allows us to ascertain the good performance of our model, since
they are similar to real life trials carried out in the recent past [4, 9].
April 9, 2019 15/22
Fig 11. Dose-densification. A numerical trial comprising 400.000 random and
uniformly chosen events in the six-dimensional parameter space (µs, σs, ρs, µn, σn, ρn)
is carried out. The parameters µ and σ take values in the intervals [0.1, 4.5] and
[0.1, 5.0] respectively, while the parameters ρ are selected in the range [0.1, 1.0]. Three
protocols are tested, being the first the concurrent reference protocol, the second the
more dose-dense in the CS drug, while the third being denser in the CNS drug. The
number of events with a particular survival fraction at the nadir of the treatment for
the reference (yellow), the CS-dense (red) and the CNS-dense (cyan) are computed,
showing the outstanding benefits of the later.
We begin by discussing the differences between the sequential and the alternating
arms. As can be seen in Fig. 10, the model echoes the conclusions discussed in
previous studies [9]. The number of events with low survival fractions are much
smaller for the alternating protocol than for the sequential arm. In particular, we find
that the latter is superior by more than a 10% of events with one-log kill. This means
that sequential administration is a better strategy, insofar as it is more dense in each
drug. However, and as discussed in [11], this is especially true in this model because
one of the drugs of the protocol is more effective than the other. Clearly put, our
model does not tell the difference between the particular biochemical mechanisms of
each drug, and therefore sequential and alternating protocols can not be distinguished
by any means, as long as such drugs cause similar tumor cell destruction.
Concerning dose-dense protocols, the results appearing in Fig. 11 leave no doubt
about the benefits of dose-densification for CNS drugs, where we obtain around a 13%
of events with one more log kills compared to the reference protocol. Unexpectedly, an
increase in the frequency of drug administration does not seem to be a recommendable
strategy if the CS drug is considered, since it barely augments the number of events
with small survival fractions. In contrast, the number of events with survival fractions
closer to one is noticeably higher. Probably, the reason behind this phenomenon is
that when the cells in the synthesis phase are erased, it is useless to keep on trying to
destroy this compartment, since it is already empty. Thus, this effect would be the
dose-dense analog to the variation of the dose-response curves commonly observed for
CS drugs, which limits the benefits of their dose intensification. Regarding the
possible benefits of protocols where the CS drug is given more frequently but at a
constant equal total dose, we have found the following results. When the frequency is
doubled and the dose per cycle is reduced to half of its control value, we see a modest
increase in the protocol. However, when the CS drug is delivered continuously, despite
being at quite low doses, we obtain a tremendous increase in overall tumor reduction.
More specifically, a 20% increase in cases bellow one-log kill is recorded. As we are
about to show by going to smaller scales of the survival fraction, the impact is even
more striking for this protocol. Accordingly, and as a colophon to this randomized
numerical trial, we compare the relative benefits obtained for the third and the fifth
protocols, which have been the two most outstanding settings.
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Fig 12. Continuation at same total dose. A numerical trial comprising 400.000
random and uniformly chosen events in the six-dimensional parameter space
(µs, σs, ρs, µn, σn, ρn) is carried out. The parameters µ and σ take values in the
intervals [0.1, 4.5] and [0.1, 5.0] respectively, while the parameters ρ are selected in the
range [0.1, 1.0]. The concurrent protocol is shown as a reference, together with a
protocol that is more dense but at an smaller dose per cycle, and the protocol with
continuously delivered CS drug as the third contending protocol. The number of
events with a particular survival fraction at the nadir for the reference (yellow), the
more frequent in the CS drug (blue) and the continuous protocol in the CS drug
(green), clearly depicting the outstanding benefits of the later.
These results are contrasted in Figs. 13(a). Not only the continuous CS protocol is
about 6% more destructive under one-log kill than the CNS-dense protocol. When the
results are plotted by zooming inside the region of survival fractions between 0 and
0.1, we find that more than 10% of the cases for the CS-continuous protocol are under
two-log kills. Moreover, by pushing further our scrutiny, we find that a non negligible
6% of the cases lie under three-log kills. We believe that these results are very relevant
from a theoretical point of view and, as discussed in the next section, have the virtue
of suggesting a possible change of paradigm concerning the future of dose-dense
chemotherapy.
3 Discussion and Conclusions
In the present paper we have introduced a quasispecies model of tumor growth for
cancer chemotherapy that allows to represent tumor masses formed by cells with
different kinetic status. Even though the dimensionality has been kept low in this
initial study, the extension of the model to reproduce heterogeneous tumors is
straightforward and can serve to explore the evolution of resistance in maintenance or
palliative chemotherapy, in addition to adjuvant therapy. Moreover, the incorporation
of other players to the dynamical scenario, as for example the cell-mediated immune
response or other types of cells from mesenchymal origin, can enable a more accurate
modeling of mixed therapies [37] and permit the simulation of toxicity as well.
The kinetic variability of our mathematical ODE model has allowed us to unveil
limitations on the principle of dose-densification that were unobserved in previous
works [10, 41]. These conclusions have been drawn on two different fronts. Firstly, our
study sheds light into the role of specific drugs in dose-dense chemotherapy. As
strongly suggested by our simulations, dose-densification of cycle-specific drugs is
envisaged to be counterproductive. On the other hand, even though CNS drugs and
dose-densification are expected to be generally beneficial, too dense protocols might
not allow the quiescent compartment to flow into the replicating one, rendering
dose-density less effective than a priori foreseen. In fact, we wonder if this effect is
behind the failure of dose-density that has been reported recently in trials of dense
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Fig 13. Comparing between the best strategies. The randomized numerical
trials previously discussed are shown for the reference protocol, the CNS-dose-dense
delivered twice more frequently and the continuously delivered protocol at low doses,
as a third arm. (a) The number of events with a particular survival fraction at the
nadir for the reference (yellow), the more frequent in the CNS drug (cyan) and the
continuous protocol in the CS drug (green), clearly depicting the outstanding benefits
of the later. (b) A zoom of the region appearing in the dashed box in the previous
figure. More than 10% of the cases reach one-log of cell kill when regrowth is avoided
by using the protocol that is continuous in the CS drug, instead of a dose-dense
protocol in the CNS drug. (c) Another zoom of the region appearing in the dashed
box of the second figure is shown. As can be seen, more than 5% of the cases reach
three-log kills when regrowth is avoided by using the protocol that is continuous in the
CS drug.
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cancer chemotherapy [16]. Evidently, this effect arises as long as the destruction in the
quiescent compartment is not too high compared to the mitotic one. Otherwise, as ǫ is
made close to 1.0, dose-density for CNS drugs would be unconditionally recommended.
Secondly, our study suggests that other possible strategies can be devised to arrest
the regrowth of the tumor between cycles. In the present work, we have proposed that
the use of CS drugs at low doses administered continuously in addition to CNS drugs
periodically delivered can be a much better schedule than dose-densification in the
CNS drug alone. The authors are aware that continuous protocols can lead to
tachyphilaxis and might also be too toxic [48], even for CS drugs. Therefore, it is not
our desire to suggest this specific strategy as a viable optimal choice, but rather to set
off a debate concerning alternatives to dose-densification, capable of producing the
same effect in a more forceful and safe way.
As an example, in previous works [10] we reasoned that the use of targeted
therapies using cytostatic agents to arrest the tumor revival between cycles might
serve to complement cytotoxic chemotherapeutic drugs. Certainly, this way of tackling
the problem presents other difficulties [10], but we note that a change in the point of
view of dose-dense chemotherapy is entailed by this perspective. In lieu of trying to
achieve maximum fractional cell kill by simply reducing the time between cycles, we
would rather put the tumors to sleep during the meantime. In this way, stasis and
destruction would cooperate to produce an enhanced overall destruction of the tumor.
Among other potential benefits, this approach could allow to extend recovery times
between cycles of chemotherapy. We should not forget that in order to damp the
increased toxicity of dose-dense protocols, growth factors are currently delivered to the
patients.
Thus, to conclude, we retake once last Paul Ehrlich’s old adage and suggest that
the periodically thrown cannonballs of cytotoxic chemotherapy might be
complemented with the magic bullets of some cytostatic targeted therapy administer
in between [49]. Then, the following hesitation immediately arises. In order to produce
the aforementioned effect without halting the rebound of the collaterally damaged
healthy tissues, can cytostatic drugs be readily designed to impact more selectively the
tumors than cytotoxic ones?
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